Sandoz reported first-half 2026 net sales of $5.761 billion, up 5% at constant currencies, and said second-quarter sales rose 7% at constant currencies as biosimilars delivered standout growth across all regions. The company said biosimilars represented a record 33% of total H1 net sales, up from 29% a year earlier, while generics returned to growth in the second quarter.
In H1, biosimilar sales increased 20% at constant currencies to $1.875 billion, led by a standout North America performance where biosimilars grew 47% at constant currencies. Sandoz said the 10 largest-selling medicines grew 14% at constant currencies and accounted for 35% of net sales. Core EBITDA rose 15% in U.S. dollars to $1.206 billion, lifting the core EBITDA margin to 20.9% from 20.0% in the prior-year period. Core diluted earnings per share increased 17% to $1.71, while management free cash flow remained $503 million.
For the second quarter, net sales were $3.005 billion, up 7% at constant currencies. Biosimilar sales rose 22% at constant currencies to $1.022 billion, while generics increased 1% at constant currencies to $1.983 billion. The company said recent biosimilar launches, including Wyost and Jubbonti, performed well.
Chief Executive Officer Richard Saynor said the quarter was particularly encouraging and underscored Sandoz’s ability to translate innovation into launch execution. He said the company added four new in-house biosimilars assets in the period, bringing its pipeline to 36 assets, and pointed to continued profitability gains and cash generation.
Sandoz confirmed its full-year 2026 guidance, expecting net sales to grow at a mid-to-high single-digit rate at constant currencies and core EBITDA margin expansion of around 100 basis points. The company also said it recently entered Brazil’s semaglutide market, advanced U.S. review of tirzepatide autoinjectors, and resolved major legacy U.S. generic litigation.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!